Crostata Di Frutta is a modern hybrid-indica strain whose precise history remains undocumented. While it descends from Project 592, the broader lineage is not publicly confirmed, and no official breeder description provides insight into its developmental timeline or genetic intent. This lack of clear origin data is reflective of its status as a strain with limited historical documentation, leaving its exact development path a subject of ongoing inquiry.

The chemical composition of Crostata Di Frutta is anchored by a terpene profile that is confirmed to progress from myrcene, caryophyllene, and terpinolene, through pinene, humulene, and ocimene, ending with minor concentrations of beta-pinene, linalool, guaiol, camphene, alpha-terpinene, limonene, gamma-terpinene, nerolidol, and bisabolol. Based on available, non-batch-specific figures, this cultivar maintains an estimated THC content of approximately 23.3% with an estimated CBD content of 0%. Cultivating this plant is of moderate difficulty in both indoor and outdoor environments, where it reaches maturity after a 70-day flowering period and produces a high yield.

In terms of therapeutic utility, Crostata Di Frutta is utilized for its documented effects of relaxation and focus, making it a frequent selection for the management of pain, stress, and sleep difficulties. As a modern hybrid-indica, it occupies a specific functional niche without currently established offspring recorded in the botanical registry. Its primary value remains its balanced physiological impact, consistent with its recorded chemical profile and reported suitability for focused, low-stress applications.